PuriCore (LSE: PURI), the life sciences company focused on the development and commercialisation of its novel, safe antimicrobial technology, today provides a pre-close trading update prior to publication on 16 April 2007 of its preliminary results for the year ended 31 December 2006. PuriCore’s platform technology mimics the human body’s production of its natural anti-microbial, hypochlorous acid, an entirely safe and non-hazardous approach to disinfection and sterilisation.
